大行评级丨里昂:康方生物上半年业绩逊预期,目标价降至177.8港元

格隆汇
Sep 01
里昂发表报告指,康方生物上半年销售同比增长32.4%,净亏损同比收窄25.6%,两者均逊市场预期。该行在业绩后修订预测,并将目标价由180.9港元下调至177.8港元,维持“跑赢大市”评级。报告指,康方生物正推进一批新颖临床资源,包括第二代免疫肿瘤(I/O)及ADC产品组合、mRNA癌症疫苗,以及针对阿尔茨海默病的Aβ/TfR抗体。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10